News and events

Theolytics doses first patient in Phase I/IIa Trial of THEO-260 in ovarian cancer

19 November 2024

Ovarian Cancer is one of the leading causes of cancer related deaths among women. Theolytics’ discovery platform was applied to identify a mechanistically differentiated adenovirus - THEO-260 - for high grade serous ovarian cancer.

OMass Therapeutics appoints Professor Steven Charlton as Chief Scientific Officer

15 November 2024

Professor Charlton, who joined OMass in 2020 as Vice President of Pharmacology, succeeds Dr. Ali Jazayeri, who is leaving the company to pursue other opportunities.

CyanoCapture at the Forefront: H2Boost deployment and COSEC Horizon grant to scale biogenic CO2 capture

10 November 2024

CyanoCapture is making significant strides in advancing sustainable carbon capture technologies with its involvement in two major projects. Both initiatives highlight CyanoCapture's commitment to pioneering carbon-negative solutions and driving progress toward a sustainable, low-carbon future.

Nucleome Therapeutics announces a strategic collaboration with Johnson & Johnson* to map genetic associations linked to autoimmune disease

21 October 2024

Nucleome Therapeutics will combine its proprietary machine learning and high-resolution 3D genomics technologies in combination with Johnson & Johnson's immunology and data science capabilities to discover new target genes and the cell types that drive autoimmune diseases, which could facilitate the classification of patients most likely to respond to therapy.

Internationally renowned academic Lee Sweetlove joins Moa

15 October 2024

Oxford University Professor to work on advanced understanding of Moa's novel modes of action.

Moa’s ground breaking science features in journal Weed Science

9 October 2024

Breaking the 30 year impasse in novel herbicide discovery.

Enara Bio raises $32.5 million Series B financing to advance first-in-class pipeline of TCR-based immunotherapies targeting novel Dark Antigens®

2 October 2024

Enara will use the money raised to advance its pipeline of TCR-based immunotherapies against novel and differentiated Dark Antigen targets for solid tumours.

OMass Therapeutics expands development team with key appointments in US and UK and announces the nomination of clinical candidate against MC2

30 September 2024

Over the last year, OMass has reportedly made significant process in advancing its pipeline and has selected its first clinical candidate targeting the MC2 receptor, a GPCR for the adrenocorticotropic hormone (ACTH).

Moa and Biomar announce bio-herbicide collaboration

16 September 2024

Moa has entered into a long-term collaboration with Biomar Microbial Technologies to strengthen its bio-herbicide and development programme.

Alchemab appoints Co-Founder Jane Osbourn as Chief Executive Officer

11 September 2024

As Co-Founder and CSO, Jane has led all aspects of Alchemab’s platform development and drug discovery activities to date and brings to the CEO role more than 30 years of biopharmaceutical industry experience.

CardiaTec secures $6.5M seed funding to advance its multi-omics drug discovery platform for cardiovascular diseases

9 September 2024

The new funds will allow CardiaTec to expand its platform and progress proprietary drug targets to wet lab validation.

Moa announces international field trial success at the ACS autumn conference in Denver

19 August 2024

Oxford University spin-out Moa Technology has announced excellent results in multi-country field trials of promising new classes of herbicide with novel modes of action recently discovered by the company.

CyanoCapture continues to make strides in the green sciences industry

11 August 2024

CyanoCapture was selected as one of the two winners of the Green Sciences Incubator challenge, which L'Oréal organised in collaboration with Genopole and Hello Tomorrow.

Bioarchitech graduates from the BioEscalator: A new chapter for innovative cancer therapy

17 July 2024

Bioarchitech's departure from the BioEscalator marks the beginning of an exciting new phase for the pioneering cancer therapy company, as it transitions to the next stage of its innovative journey.

Nucleome Therapeutics appoints Mark Bodmer as Chief Executive Officer

15 July 2024

Nucleome Therapeutics (‘Nucleome’ or ‘the Company’), a biotechnology company using spatial genomics to discover precision medicines for complex diseases, announces today that it has appointed Dr. Mark Bodmer as Chief Executive Officer with effect from 24 July.

Moa harvests global deal for new herbicide

7 July 2024

Agricultural biotech firm Moa Technology has signed a research and commercial partnership with Nufarm, a global agricultural innovator based in Melbourne, Australia.

GSK enters into a multi-year data licence agreement with Ochre Bio to further investigate the drivers of liver disease

11 June 2024

Ochre and GSK will create a foundational liver biology dataset that could have the potential to further improve translation of novel therapies for liver diseases.

Alchemab advances a novel antibody with potential in Parkinson’s disease with support from The Michael J. Fox Foundation

5 June 2024

Former BioEscalator tenant Alchemab Therapeutics continues to make significant strides in Parkinson's disease research, recently receiving a substantial grant from The Michael J. Fox Foundation for Parkinson's Research (MJFF) to advance its innovative antibody discovery program.

MediMabBio's graduation from the BioEscalator: A testament to innovation and growth

5 June 2024

MediMab Biotherapeutics announces its graduation from the BioEscalator. This move represents a major milestone for the company as it relocates to Abingdon Science Park, positioning itself for further expansion and cutting-edge research in immuno-oncology.

CardiaTec joins the BioEscalator - AI in cardiovascular drug discovery

17 April 2024

The BioEscalator welcomes CardiaTec, a spin-out company from the University of Cambridge that employs computational methods to decode the biology behind cardiovascular disease.

Cookies on this website

Follow us on LinkedIn